Evidence map›Paper›PMID 24844401›Full record

ArticleThe Prostate2014

Genetic variation across C-reactive protein and risk of prostate cancer.

Sarah C Markt, Jennifer R Rider, Kathryn L Penney, Fredrick R Schumacher, Mara M Epstein, Katja Fall, Howard D Sesso, Meir J Stampfer, Lorelei A Mucci

Open access · greenAbstract read
In one paragraph

Article in The Prostate, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Sarah C MarktDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Jennifer R Rider
Kathryn L Penney
Fredrick R Schumacher
Mara M Epstein
Katja Fall
Howard D Sesso
Meir J Stampfer
Lorelei A Mucci
Harvard University · USBrigham and Women's Hospital · USÖrebro University · SEUniversity of Southern California · US

Funding

Training Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3M
Physicians' Health Study II: Prevention Trial of VitaminsR01CA097193 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GAZIANO, J. MICHAEL · 2002 to 2011
$15.7M
NUTRITIONAL BIOCHEMISTRY MARKERS OF CANCER AND MIR01CA042182 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI MA, JING · 1986 to 2007
$5.3M
Nutritional Epidemiology of Cancer Education and Career Development ProgramR25CA098566 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI STAMPFER, MEIR · 2003 to 2013
$4.5M
Growth Factors and Lethal Prostate Cancer SignatureR01CA141298 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI STAMPFER, MEIR · 2010 to 2013
$2.2M
RANDOMIZED TRIAL OF ASPIRIN AND MORTALITYR01CA040360 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1985 to 2002
$775k
TRIAL OF ASPIRIN AND BETA-CAROTENE IN U S MD'SR01HL034595 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1985 to 1991
–
NCI NIH HHS CA097193NCI NIH HHS CA141298NCI NIH HHS CA40360NCI NIH HHS CA42182NCI NIH HHS R01 CA034944NCI NIH HHS R01 CA040360NCI NIH HHS R01 CA042182NCI NIH HHS R01 CA097193NCI NIH HHS R01 CA141298NCI NIH HHS R25 CA098566NCI NIH HHS T32 CA009001NCI NIH HHS T32 CA09001-35NHLBI NIH HHS R01 HL026490NHLBI NIH HHS R01 HL034595
6 · The paper itself

Abstract

backgroundInflammation has been hypothesized to play an important etiological role in the initiation or progression of prostate cancer. Circulating levels of the systemic inflammation marker C-reactive protein (CRP) have been associated with increased risk of prostate cancer. We investigated the role of genetic variation in CRP and prostate cancer, under the hypothesis that variants may alter risk of disease.

methodsWe undertook a case-control study nested within the prospective Physicians' Health Study among 1,286 men with incident prostate cancer and 1,264 controls. Four single-nucleotide polymorphisms (SNPs) were selected to capture the common genetic variation across CRP (r(2)  > 0.8). We used unconditional logistic regression to assess the association between each SNP and risk of prostate cancer. Linear regression models explored associations between each genotype and plasma CRP levels.

resultsNone of the CRP SNPs were associated with prostate cancer overall. Individuals with one copy of the minor allele (C) in rs1800947 had an increased risk of high-grade prostate cancer (OR: 1.7; 95% CI: 1.1-2.8), and significantly lower mean CRP levels (P-value <0.001), however, we found no significant association with lethal disease. Mean CRP levels were significantly elevated in men with one or two copies of the minor allele in rs3093075 and rs1417939, but these were unrelated to prostate cancer risk.

conclusionOur findings suggest that SNPs in the CRP gene are not associated with risk of overall or lethal prostate cancer. Polymorphisms in CRP rs1800947 may be associated with higher grade disease, but our results require replication in other cohorts.

Indexed as

Polymorphism, Single NucleotideAdultAgedAged, 80 and overCase-Control StudiesC-Reactive ProteinGenetic VariationHumansMaleMiddle AgedProspective StudiesProstatic NeoplasmsRiskC-Reactive ProteinCRP SNPsinflammationprostate cancer

Identifiers

PMID24844401
PMCPMC4063346
OpenAlexW1646975696

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.